Characteristics of studies included in the systematic review
| Cohort | Study (author) | Mean age (95% CI) | Sample size | Male (%) | AMI prevalence (%) | Median presentation time (min) | Median time from presentation to first sample (min) | Median time between first and second sample (min) | hs-cTn assay |
| APACE (derivation) | Reichlin et al 6 | 63 (50 to 75) | 436 | 70 | 17 | NA | NA | NA | hs-cTnT-Roche |
| Gimenez et al 7 | 62 (49 to 62) | 905 | 69 | 21 | NA | NA | NA | hs-cTnI-Abbott | |
| APACE-BACC | Twerenbold et al 28 | 62 (50 to 74) | 4368 | 67 | 17 | NA | 0 | 60 (59–68) | hs-cTnT-Roche and hs-cTnI-Abbott |
| APACE only | Boeddinghaus et al 29 | 62 (49 to 75) | 1347 | 69 | 18 | NA | NA | NA | hs-cTnI-Siemens |
| HIGHSTEAC | Chapman et al 30 31 | 62±14.2 | 406 | 61 | 8 | 199 | 28 | 65 (60–73) | hs-cTnI-Abbott and hs-cTnI-Siemens |
| Barcelona | Duran-Cambra et al 16 | 68±15 | 187 | 64 | 13 | NA | NA | NA | hs-cTnT-Roche |
| Parkland | Vigen et al 15 | 55 | 536 | 56 | 2 | NA | NA | NA | hs-cTnT-Roche |
| TRAPID | Mueller et al 9 | 62 (50 to 74) | 1282 | 63 | 15 | 108 (60–174) | NA | NA | hs-cTnT-Roche |
| Japan–Taiwan | Shiozaki et al 14 | 72 (59 to 81) | 413 | 61 | 14 | NA | NA | NA | hs-cTnT-Roche |
| HIGH-US | Nowak et al 35 | 56.7±12.9 | 2111 | 57 | 15 | NA | NA | NA | hs-cTnI-Siemens |
| REACTION-US | Gandolfo et al 34 | NA | 543 | NA | 8 | NA | NA | NA | hs-cTnT-Roche |
| Fuwai | Lin et al 36 | 59.5 (58.2 to 60.8) | 283 | NA | 32 | NA | NA | NA | hs-cTnI-Abbott |
| Bangkok* | Ruangsomboon et al 32 | 67±14.2 | 65 | 40 | NA | 186 | 14.9 | NA | hs-cTnT-Roche |
| Lund* | Mokhtari et al 33 | 61±7.5 | 1038 | 54 | NA | NA | NA | NA | hs-cTnT-Roche |
*These cohorts were included for analysis of secondary outcome, that is, major adverse cardiac events or mortality.
AMI, acute myocardial infarction; APACE, advantageous predictors of acute coronary syndromes evaluation; BACC, biomarkers in acute cardiac care; HIGHSTEACS, high-sensitivity troponin in the evaluation of patients with acute coronary syndrome; HIGH-US, high-sensitivity cardiac troponin I assays in the United States; hs-cTn, high-sensitivity cardiac troponin; NA, Not available; REACTION-US, Rapid evaluation of acute myocardial infarction in the United States; TRAPID, the high sensitivity cardiac troponin T assay for rapid rule-out of acute myocardial infarction.